Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial

BACKGROUND: Favipiravir, an oral, RNA-dependent RNA polymerase inhibitor, has in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite limited data, favipiravir is administered to patients with coronavirus disease 2019 (COVID-19) in several countries. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Holubar, Marisa, Subramanian, Aruna, Purington, Natasha, Hedlin, Haley, Bunning, Bryan, Walter, Katharine S, Bonilla, Hector, Boumis, Athanasia, Chen, Michael, Clinton, Kimberly, Dewhurst, Liisa, Epstein, Carol, Jagannathan, Prasanna, Kaszynski, Richard H, Panu, Lori, Parsonnet, Julie, Ponder, Elizabeth L, Quintero, Orlando, Sefton, Elizabeth, Singh, Upinder, Soberanis, Luke, Truong, Henry, Andrews, Jason R, Desai, Manisha, Khosla, Chaitan, Maldonado, Yvonne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047233/
https://www.ncbi.nlm.nih.gov/pubmed/35446944
http://dx.doi.org/10.1093/cid/ciac312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047233/
https://www.ncbi.nlm.nih.gov/pubmed/35446944
http://dx.doi.org/10.1093/cid/ciac312

Ejemplares similares